Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.38 |
| ▸ | WEE1 | P30291 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8481386 | 0.89 | EGLN3 (0.40) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL22117141 | 0.88 | EGLN3 (0.42) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL20622958 | 0.86 | TBXAS1 (0.49) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL20623229 | 0.86 | TBXAS1 (0.49) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL26206833 | 0.86 | TBXAS1 (0.49) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL11463256 | 0.84 | EGLN3 (0.45) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL7001982 | 0.81 | EGLN3 (0.38) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL8032072 | 0.81 | TBXAS1 (0.57) | EGLN3TBXAS1ALDH1A1TDP1LMNA | |
| SCHEMBL28774336 | 0.81 | TBXAS1 (0.42) | EGLN3TBXAS1WEE1ALDH1A1TDP1 | |
| SCHEMBL11598612 | 0.80 | TBXAS1 (0.40) | EGLN3TBXAS1WEE1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5908960-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| US-9982095-B2 | Substituted organopolysiloxanes and use thereof | PHOSPHONICS LTD (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20090098082-A1 | substiuted organopolysiloxanes and use thereof | PHOSPHONICS LTD (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1786850-B1 | SUBSTITUTED ORGANOPOLYSILOXANES AND USE THEREOF | PHOSPHONICS LTD (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6008372-A | ANTICARCINOGENIC, ANTIRESTENOSIS AND ANTIPSORIASIS AGENT | WARNER-LAMBERT COMPANY (US) | 1999-12-28 | — | — | US | disclosed |
| US-5908960-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | EGLN3 608/4885TBXAS1 714/4885WEE1 871/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | EGLN3 956/4885TBXAS1 885/4885WEE1 1184/4885 |
| US-20090098082-A1 | substiuted organopolysiloxanes and use thereof | OR10J3, SOST, ITGB3 | EGLN3 2411/4885TBXAS1 3210/4885WEE1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.